

**ASX Announcement**  
**1 December 2025 (Melbourne, Australia)**  
**Optiscan Imaging Ltd (ASX:OIL)**

**Investor Webinar Invite**

**Optiscan Imaging Limited (ASX:OIL)** ('Optiscan' or the 'Company') is pleased to announce that it will be holding an investor webinar on Thursday 4 December 2025.

The webinar will be presented by Optiscan CEO and Managing Director, Dr Camile Farah. It will be followed by a short Q&A session.

Optiscan now has a long funding runway to further progress its development and commercialisation strategy post the Company's recently completed \$17.75m equity raise.

The webinar will discuss a host of current and upcoming clinical- and regulatory-related activities that together form the Company's well considered growth strategy. Specific topics to be discussed in the webinar include:

- The ever-expanding market opportunities for Optiscan's product catalogue that includes InVue<sup>®</sup>, InForm<sup>™</sup> and InSpecta<sup>™</sup>
- Current and upcoming clinical and regulatory activities involving InVue<sup>®</sup>, InForm<sup>™</sup> and InSpecta<sup>™</sup> – including groundwork for US-based clinical studies
- The significance of the now underway breast cancer study at the Royal Melbourne Hospital (utilising the InVue<sup>®</sup> and InForm<sup>™</sup> devices)
- Next steps in the clinical and commercialisation journey for the InSpecta<sup>™</sup> veterinary device
- How the recently signed Collaboration Agreement with Australian Clinical Labs supports the deployment and testing of the InForm<sup>™</sup> digital pathology platform
- An explanation of the benefits flowing from other existing and pending collaborations, including those with respected groups like the Mayo Clinic.

**Optiscan Imaging Limited Investor Webinar Registration Details:**

**DATE:** Thursday 4 December 2025

**TIME:** 11.00AM AEDT

**FORMAT:** Zoom

**Reference Documents:**

**Please register in advance using the following link:**

[https://us02web.zoom.us/webinar/register/WN\\_QqF-s3EiQgiUvhTKjloikw](https://us02web.zoom.us/webinar/register/WN_QqF-s3EiQgiUvhTKjloikw)

After registering, you will receive a confirmation email containing information about joining the webinar.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

### For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: [ceo@optiscan.com](mailto:ceo@optiscan.com)

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

### About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit [www.optiscan.com](http://www.optiscan.com) or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

### Disclaimer

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*